Protocol Details
Evaluation of the Gastrinoma in Patients with Zollinger-Ellison Syndrome
This study is NOT currently recruiting participants.
Summary
Number | 90-DK-0137 |
Sponsoring Institute | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail | Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18
Max Age: 100 |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Zollinger-Ellison Syndrome;
Natural History |
Recruitment Keyword(s) | None |
Condition(s) | Zollinger Ellison Syndrome |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Institute of Diabetes and Digestive and Kidney Diseases |
This protocol concerns the approach to the localization, diagnosis of MEN1 and management of the tumor and the tissue samples in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor, investigations for MEN1 the subsequent management of the tumor and tissue samples for research.
Eligibility
INCLUSION CRITERIA:
New patients will be evaluated initially as described in the protocol entitled, "Diagnostic evaluation of patients with suspected abnormalities of gastric secretion" (89-DK-0005).
Only those patients that are being treated under the protocol entitled, "Medical Therapy of Zollinger-Ellison Syndrome" (protocol # 89-DK-0015) will be entered into this tumor localization and management protocol.
Citations:
Zollinger-Ellison syndrome: current concepts in diagnosis and management Current diagnosis and management of Zollinger-Ellison syndrome Pathomorphologic, biochemical and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome)
Contacts:
Clinical Trials Number:
NCT00001254Protocol Details
Evaluation of the Gastrinoma in Patients with Zollinger-Ellison Syndrome
This study is NOT currently recruiting participants.
Summary
Number | 90-DK-0137 |
Sponsoring Institute | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail | Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18
Max Age: 100 |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Zollinger-Ellison Syndrome;
Natural History |
Recruitment Keyword(s) | None |
Condition(s) | Zollinger Ellison Syndrome |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Institute of Diabetes and Digestive and Kidney Diseases |
This protocol concerns the approach to the localization, diagnosis of MEN1 and management of the tumor and the tissue samples in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor, investigations for MEN1 the subsequent management of the tumor and tissue samples for research.
Eligibility
INCLUSION CRITERIA:
New patients will be evaluated initially as described in the protocol entitled, "Diagnostic evaluation of patients with suspected abnormalities of gastric secretion" (89-DK-0005).
Only those patients that are being treated under the protocol entitled, "Medical Therapy of Zollinger-Ellison Syndrome" (protocol # 89-DK-0015) will be entered into this tumor localization and management protocol.
Citations:
Zollinger-Ellison syndrome: current concepts in diagnosis and management Current diagnosis and management of Zollinger-Ellison syndrome Pathomorphologic, biochemical and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome)
Contacts:
Clinical Trials Number:
NCT00001254